Our Company

Daniel Carbery

President and CEO

Daniel Carbery is the President and General Manager of Amring. He is responsible for creating the strategic vision and operating plan for the company. Mr. Carbery is charged with driving a talented leadership team to build a new generic drug company, one that’s based on high quality products, committed employees, enduring and trusting customer relationships, global business partnerships and complete integrity.

Mr. Carbery has a successful track record building and leading franchises and serving a national consumer audience through healthcare and retail distribution channels. Before becoming a founding leader and head of Amring, Mr. Carbery was Chief Executive Officer and Board Director for Axcentria Pharmaceuticals. Previously, he held positions of increasing managerial and executive responsibility for companies including Endo Pharmaceuticals, Procter & Gamble, Nabisco and GlaxoSmithKline.

Mr. Carbery has expertise in commercial management, product development, and total supply chain activities at the national and global levels. He has proved to be a sophisticated strategist and an expert at leading operations across a range of functions, including R&D, engineering, plant operations, marketing, product development and market development. Mr. Carbery has provided strategic and business counsel to major organizations and startups.

Mr. Carbery graduated from Princeton University with a degree in Chemical Engineering and earned his MBA from Rutgers University.

Tatyana Kosheleva, CPA, MBA

VP Treasurer & CFO

Tatyana Kosheleva is Head, Finance and Corporate Treasurer for Amring Pharmaceuticals Inc. In this role, Ms. Kosheleva is responsible for supporting the company’s financial growth. She oversees forecasting and planning, accounting, liquidity management, internal controls, compliance, purchasing, and bank and audit relationship management. Ms. Kosheleva is a member of Amring’s Executive Board, and reports directly to the President of Amring.

Ms. Kosheleva has extensive international financial and operational expertise, with a career that spans more than two decades and four countries. Before joining Amring, she was Finance Director at Russian subsidiary of Ferring Pharmaceuticals. Prior to that, Ms. Kosheleva served as Chief Financial Officer at DST Global Solutions, a London-based subsidiary of DST Systems, with offices in nine countries.

Ms. Kosheleva is a licensed CPA and holds an MBA from Thunderbird School of Global Management, a part of the Arizona State University.

Marina Volin, Esq.

VP, General Counsel & Corporate Secretary

Marina joined Amring Pharmaceuticals in May 2020 as Vice President, General Counsel & Corporate Secretary. She oversees all legal matters for the company including contractual agreements, corporate governance, intellectual property, compliance matters and due diligence for business development opportunities.
With more than 20 years of experience representing pharmaceutical companies, Marina came to Amring from Kintai Therapeutics of Cambridge, MA where she served as Vice President, Head of Legal and Intellectual Property. Prior to that, she served as Intellectual Property and Corporate Attorney for Windtree Therapeutics, Inc. (formerly Discovery Labs) of Warrington, PA. Marina began her legal career with the law firm Caesar Rivise, PC of Philadelphia, PA. Prior to studying law, Marina served as Scientific Assistant at the Fox Chase Cancer Center, Philadelphia, PA.

Marina earned her Juris Doctorate degree from the Temple University School of Law in Philadelphia and Master of Science and Bachelor of Science degrees in Chemical Engineering from the Gubkin Russian University of Oil and Gas in Moscow. She is a member of the New Jersey and Pennsylvania Bar Associations.

Thomas Sammler

Head of Sales and Marketing

As Head, Sales and Marketing, Mr. Sammler is responsible for the strategy and tactical execution of the Amring commercial product portfolio. He leads the identification and pursuit of profitable sales growth at the national, regional, and local level, across Retail, Specialty and Institutional Pharmacy. He also helps carry out growth initiatives, such as business development activities, to ensure strong, sustained P&L performance for the company.

Before joining Amring in September 2015, Mr. Sammler was Director, Sales Operations for Impax Laboratories. In that position, he managed sales operations during the company’s integration with the Tower Holding companies. Previously, Mr. Sammler held various marketing and financial positions at CorePharma, Sandoz, Endo Pharmaceuticals and DuPont/DuPont Merck. He has experience driving revenues for both generic and branded pharmaceutical products and leading a diverse range of commercial operations, from sales teams and product marketing to supply chain logistics and strategic planning.

Mr. Sammler graduated with a B.S. in Accounting from Widener University and earned his MBA in Pharmaceutical Marketing from Saint Joseph’s University.

Erika Geimonen, Ph.D., M.S.

VP, Business Development

Erika Geimonen serves as Vice President, Business Development for Amring Pharmaceuticals. She is responsible for analyzing the market landscape to identify opportunities in product licensing, partnering and acquisitions that will help Amring Pharmaceuticals reach its strategic objectives. She evaluates the company’s business development opportunities, including M&A, in-licensing, divestment, alliances and out-licensing. She also leads the due diligence team that oversees all company acquisitions.

Dr. Geimonen has more than 23 years of experience in business development and research. Before joining Amring Pharmaceuticals, she was the Chief Operating Officer and Vice President, Business Development for Dynamis Therapeutics. In that position, she was responsible for all business development activities, managing operations, and raising capital for the company. Previously, Dr. Geimonen held business development positions at XBiotech, Luitpold Pharmaceuticals and Schering-Plough. Earlier in her career Dr. Geimonen held a series of research roles.

Dr. Geimonen co-chairs the Philadelphia chapter of Licensing Executives Society. She earned her M.S. in Biology and Ph.D. in Biology and Biochemistry from Moscow State University in Russia and an M.S. in Management and Policy from the College of Business at the State University of New York at Stony Brook.